Blood · 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Campbell Peter J, Griesshammer Martin, Döhner Konstanze, Döhner Hartmut, Kusec Rajko, Hasselbalch Hans C, Larsen Thomas Stauffer, Pallisgaard Niels, Giraudier Stéphane, Le Bousse-Kerdilès Marie-Caroline, Desterke Christophe, Guerton Bernadette, Dupriez Brigitte, Bordessoule Dominique, Fenaux Pierre, Kiladjian Jean-Jacques, Viallard Jean-François, Brière Jean, Harrison Claire N, Green Anthony R, Reilly John T
Аннотация
Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01).